(3R)-5-hydroxy-3-methylpentanoic acid | 145610-22-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (3R)-5-hydroxy-3-methylpentanoic acid
• CAS: 145610-22-6
• 化学式: C₆H₁₂O₃
• 分子量: 132.159
• InChiKey: MLYKGFBBFUYWHJ-RXMQYKEDSA-N

物化性质

• 沸点：
  263.1±23.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3R)-5-hydroxy-3-methylpentanoic acid 在 对甲苯磺酸 作用下， 以 苯 为溶剂， 反应 4.0h， 以701 mg的产率得到(4R)-4-methyltetrahydro-2H-pyran-2-one
  参考文献：
  名称：

  Prochiral recognition in the reaction of 3-substituted glutaric anhydrides with chiral secondary alcohols

  摘要：

  The scope of a previously-reported process for the desymmetrization 3-substituted glutaric anhydrides has been investigated. Thus, prochiral anhydrides 5-9 react with 1-(1'-naphthyl)ethanol (2) to give glutaric acid half-esters, which are esterified by treatment with diazomethane to obtain the corresponding diesters 16-20. The degree of prochiral recognition is inversely related to the steric bulk of the stereodifferentiating group, with the series TBDMSO, Me, Et, Ph, i-Pr, and t-Bu giving ratios of 40:1, 16:1, 14:1, 8:1, 7:1, and 1:3, respectively. The absolute sense of the prochiral recognition was established by conversion of two of the diesters, 16a and 18a, into 3-substituted valerolactones (22a, 22c) of known absolute configuration.

  DOI：

  10.1021/jo00053a027
• 作为产物：
  描述：

  methyl 3-(R)-methyl-5-hydroxypentanoate 在 sodium hydroxide 作用下， 以875 mg的产率得到(3R)-5-hydroxy-3-methylpentanoic acid
  参考文献：
  名称：

  Prochiral recognition in the reaction of 3-substituted glutaric anhydrides with chiral secondary alcohols

  摘要：

  The scope of a previously-reported process for the desymmetrization 3-substituted glutaric anhydrides has been investigated. Thus, prochiral anhydrides 5-9 react with 1-(1'-naphthyl)ethanol (2) to give glutaric acid half-esters, which are esterified by treatment with diazomethane to obtain the corresponding diesters 16-20. The degree of prochiral recognition is inversely related to the steric bulk of the stereodifferentiating group, with the series TBDMSO, Me, Et, Ph, i-Pr, and t-Bu giving ratios of 40:1, 16:1, 14:1, 8:1, 7:1, and 1:3, respectively. The absolute sense of the prochiral recognition was established by conversion of two of the diesters, 16a and 18a, into 3-substituted valerolactones (22a, 22c) of known absolute configuration.

  DOI：

  10.1021/jo00053a027

文献信息

• PROCESS FOR THE PREPARATION OF INTERMEDIATE COMPOUNDS OF DRUGS
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1188749A1

  公开（公告）日：2002-03-20

  The present invention relates to a process for preparing selectively compound (I), (1S, 5S, 6R, 7R)-2-aza-7-chloro-5-methyl-3-oxobicyclo[4.1.0]heptane, by preparing compound (II) from compound (V) through compound (III) via a series of reactions, and by crystallizing the obtained compound (II); and the novel intermediate compound represented by the structural formula (III) and hydrate salts thereof.

  本发明涉及一种通过从化合物（V）经过一系列反应制备化合物（II）并通过结晶得到的化合物（II），来选择性制备化合物（I）（1S，5S，6R，7R）-2-aza-7-chloro-5-methyl-3-oxobicyclo[4.1.0]heptane的方法；以及由结构式（III）表示的新型中间体化合物及其水合盐。
• DIURETICS
  申请人：Ali Amjad

  公开号：US20120208838A1

  公开（公告）日：2012-08-16

  A compound having the structure (I) wherein R is selected from the group consisting of 1) and 2), or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.

  具有结构（I）的化合物，其中R从1）和2）组成的群体中选择，或其药学上可接受的盐，以及使用这些化合物治疗高血压的方法。
• Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US10953027B2

  公开（公告）日：2021-03-23

  Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

  本文公开了活性剂、含有活性剂的组合物、含有活性剂的单位剂型以及活性剂的使用方法，例如用于治疗代谢紊乱或非酒精性脂肪肝或调节代谢标志物或非酒精性脂肪肝标志物。
• Asymmetric hydrogenation of unsaturated carboxylic acids catalyzed by BINAP-ruthenium(II) complexes
  作者：Tetsuo Ohta、Hidemasa Takaya、Masato Kitamura、Katsunori Nagai、Ryoji Noyori

  DOI：10.1021/jo00390a043

  日期：1987.7
• MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US20200101030A1

  公开（公告）日：2020-04-02

  Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers, or carbamate linkers. The moieties can be alcohol cores, amine cores, and/or acyls. Also disclosed are compositions containing multibiotic agents and methods of using the multibiotic agents.